Sten K Johnson Foundation award “Development of a predictive and stratifying biomarker”
Histone 1.3 – a new and unique biomarker for pancreatic cancer
Pancreatic cancer is one of the most serious forms of cancer. The difficulty is to identify pancreatic cancer “early”. There are no biomarkers in either blood or tissue to provide diagnosis, prognostic / predictive help and support in selecting therapy. Research has now found a pancreatic cancer-specific marker (Histone 1.3; H1.3). The purpose is now to validate the finding in a larger patient group with pancreatic cancer. The marker may hopefully constitute a potential prognostic factor that both strengthens diagnostics and helps with the choice of therapy.
Reccan Diagnostics / Roland Andersson
